August 9 (Reuters) – Vinay Prasad returns to its role that supervises the vaccine, gene therapy and the regulation of blood products in the United States Food and Drug Administration a little more than a week after leaving the agency.

“At the request of the FDA, Dr. Vinay Prasad is resuming the leadership of the Biological Evaluation and Research Center,” said the spokesman for Human Services of the United States. UU. Andrew Nixon in a statement sent by email to Reuters.

Prasad left the agency on July 30 after a few months as director of the center.

Endpoints News first reported Prasad’s return.

Prasad, an oncologist who was a fierce critic of vaccines and masks of the US COVID-19, was appointed director of the center by the FDA Commissioner, Marty Makary in May.

In this photo provided by the United States Drug and Food Administration, Vinay Prasad smiles for a portrait. (FDA American through AP)
In this photo provided by the United States Drug and Food Administration, Vinay Prasad smiles for a portrait. (FDA American through AP)

Via News

Criticisms of Prasad’s mandate intensified around the management of the agency of a gene therapy for Duchenne’s muscle dystrophy of Sarepta Therapeutics.

The therapy approved by the FDA played a role in the death of two teenagers who had advanced DMD. After a third death in an experimental gene therapy separated from the company, the FDA asked Sarepta on July 18 to stop all shipments from the approved DMD therapy, saying that he had security concerns.

The FDA changed course in Sarepta on July 28 and said that shipments to the main group of patients for the medication could be restarted.

Laura Loomer, an extreme right and ally activist of the president of the United States, Donald Trump, published a blog on July 20 in which he called Prasad a “progressive leftist saboteator” who was undermining the agency’s work.

Prasad was a doctor who joined the University of California agency, San Francisco. He has had periods at the National Cancer Institute and National Health Institutes.

The FDA and other health agencies have seen multiple shakes in recent months under the leadership of the Secretary of Health of the United States Robert F. Kennedy Jr.

20 years ofFreeJournalism

Your support feeds our mission

Your support feeds our mission

For two decades, News themezone has been brave, unwavering and implacable in the search for truth. Support our mission of staying for the next 20: we cannot do this without you.

We remain committed to providing unwavering journalism and based on facts that everyone deserves.

Thanks again for your support on the way. We are really grateful for readers like you! His initial support helped us take us here and reinforced our writing room, which kept us strong during uncertain times. Now as we continue, we need your help more than ever. We hope you join us once again.

We remain committed to providing unwavering journalism and based on facts that everyone deserves.

Thanks again for your support on the way. We are really grateful for readers like you! His initial support helped us take us here and reinforced our writing room, which kept us strong during uncertain times. Now as we continue, we need your help more than ever. We hope you join us once again.

Support News themezone

Already contributed? Log in to hide these messages.

(Rishabh Jaiswal and Ananya Palyekar report in Bengaluru; Mark Porter edition)